Optimapharm ads

Enrolment not going as expected? Don’t leave it too late to explore a contingency plan. Acting early can help protect downstream timelines and budgets. Optimapharm offers 2x more regulatory and clinical monitoring coverage than the average CRO across Europe, helping sponsors access diverse patient pools and fast-tracked regulatory pathways. Over the last 5 years, we’ve supplemented 490+ projects to extend geographical reach and rescued 50+ projects facing recruitment and delivery challenges. If enrolment is falling behind plan, now is the time to understand your options. 👉 Request a no-obligation feasibility assessment.

What does it take to exceed recruitment targets in a multicentre ulcerative colitis study? Optimapharm supported this Phase IIb clinical trial across 11 European sites, with an ambitious recruitment target and a strong focus on quality throughout delivery. The outcome? Recruitment exceeded target, alongside strong quality results, including two audits with no critical findings. But the results only tell part of the story. How did the team get there? Watch our latest case study to find out. 👇

Optimapharm is featured in STAT News! 🎉 Could the proposed Biotech Investment National Security Act (BINSA) of 2026 change the global biotech landscape in unexpected ways? The bigger opportunity goes beyond geopolitics. The biotechs that win will be those running smarter global clinical strategies, choosing the right countries for the right trials across North America, Europe and beyond. Better patient access. Faster recruitment. High-quality data. Smarter execution. The right global footprint can unlock more and move development faster. Featuring Paul Miller, Pavle Vukojevic and Miguel Angel Salcedo. 👉 Read the full article here: https://lnkd.in/d33HZi6F

Optimapharm is featured in STAT News! 🎉 Could the proposed Biotech Investment National Security Act (BINSA) of 2026 change the global biotech landscape in unexpected ways? The bigger opportunity goes beyond geopolitics. The biotechs that win will be those running smarter global clinical strategies, choosing the right countries for the right trials across North America, Europe and beyond. Better patient access. Faster recruitment. High-quality data. Smarter execution. The right global footprint can unlock more and move development faster. Featuring Paul Miller, Pavle Vukojevic and Miguel Angel Salcedo. 👉 Read the full article here: https://lnkd.in/d33HZi6F

Delighted to be featured in STAT News with my colleagues Pavle Vukojevic and Miguel Angel Salcedo where we touch on the potential impact of the Biotech Investment National Security Act (BINSA) and why biotech companies should be adopting smarter, more resilient global clinical development strategies irrespective of geopolitical shifts. https://lnkd.in/e_uSWHZn

Travelling to Madrid in October? Join Optimapharm in Madrid on 24 October for an exclusive private reception bringing together biotechnology executives, clinical development leaders and principal investigators. 📍 Real Casino de Madrid | Neptune Room 🕗 20:00 CET 🎟️ Limited places available Connect with peers. Exchange perspectives. Explore new opportunities for collaboration across the oncology clinical development ecosystem. A private evening, meaningful conversations and an exceptional setting. Request your invitation today: https://lnkd.in/dmC4xgFf